* required
*=required
with Scott Isaacs, MD, FACE, FACP and Barton Isaac, PharmD
NASH definitions, epidemiology and risk factors with Meena B. Bansal, MD
Normal liver thyroid hormone function and dysregulation in NAFLD/NASH with Eveline Bruinstroop, MD
Thyroid hormone effect on autophagy, mitophagy, inflammation and fibrosis in NAFLD/NASH with Eveline Bruinstroop, MD
THR-β agonists for the treatment of NASH with Meena B. Bansal, MD
Definitions and Epidemiology; Pathophysiology; Natural History of the Disease; Morbidity and Mortality with Christina Hanson, MS, FNP
Identifying Risk Factors; Patient Identification; Patient Perspective with Ann Moore, FNP-C
Treating Patients With NASH and Significant Fibrosis – Are we doing Enough? with Prof Quentin M. Anstee, MD
Treating Patients With NASH and Significant Fibrosis – Now and in the Future with Prof Jörn M. Schattenberg, MD
Treating Patients With NASH and Significant Fibrosis – What does the Future Hold? with Prof Stephen A. Harrison, MD, FACP, FAASLD
Definitions, Epidemiology & Comorbidities; Pathophysiology with Mazen Noureddin, MD, MHSc
Morbidity & Mortality; Patient Identification; Patient Perspective with Marcelo Kugelmas, MD, FAASLD, FACP
Podcasts
